{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:26:15Z","timestamp":1781277975774,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.euf.2020.05.004","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T09:19:20Z","timestamp":1591694360000},"page":"566-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Stratification of Intermediate-risk Non\u2013muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies"],"prefix":"10.1016","volume":"7","author":[{"given":"Francesco","family":"Soria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abufaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian M.","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2020.05.004_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0025","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0030","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer\u2014the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0050","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.eururo.2011.12.055","article-title":"Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma","volume":"61","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An Individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","article-title":"Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation","volume":"34","author":"Lammers","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0065","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance bacillus Calmette-Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00345-010-0514-x","article-title":"Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer","volume":"28","author":"Kohjimoto","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","article-title":"What to do during bacillus Calmette-Gu\u00e9rin shortage? Valid strategies based on evidence","volume":"28","author":"Abufaraj","year":"2018","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2020.05.004_bib0080","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0895-4356(01)00341-9","article-title":"Internal validation of predictive models: efficiency of some procedures for logistic regression analysis","volume":"54","author":"Steyerberg","year":"2001","journal-title":"J Clin Epidemiol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920301152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920301152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:51:03Z","timestamp":1762498263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456920301152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2405456920301152"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2020.05.004","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stratification of Intermediate-risk Non\u2013muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2020.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}